Health professional risk communication

Tridural (tramadol HCl extended release tablets) - Removal of Tablet Markings in Certain Lots

Starting date:
October 26, 2015
Posting date:
October 26, 2015
Type of communication:
Dear Healthcare Professional Letter
Source of recall:
Health Canada
Important Safety Information
Healthcare Professionals, General Public
Identification number:


Pharmacists and pharmacy staff.

Key messages

  • The tablet markings (“LP 100”, “LP 200” and LP 300”) that help differentiate the 3 strengths of Tridural® tablets have been removed on certain lots.
  • The lack of tablet markings may cause confusion to patients and increase the risk of medication errors.
  • There are currently both marked and unmarked tablets on the market.
  • Pharmacists can continue to dispense either marked or unmarked tablets, as there has been no change in formulation. Patients should be informed in order to avoid any potential confusion.
  • Markings on Tridural® tablets will be reinstated on all future lots.



As of April 2014, Paladin Labs Inc. stopped printing tablet markings (“LP 100”, “LP200” and “LP 300”) on the associated strengths of Tridural® (tramadol HCl extended release tablets).  There was no change to the formulation and there is no quality issue with the product.  For a period of time, there may be marked and unmarked tablets on the market. 

In order to avoid any potential confusion to the pharmacist or patient, the company will be reinstating markings on the tablets starting with the next manufactured lots.

Products affected

The following products are affected:
Manufacturer Product DIN # Product Code Lot # Expiry Date
Paladin Labs Inc. Tridural® 100mg 02296381 5000093
(UPC 6 2879100401 6)
140878R2 Sep 2016
141930R1 Dec 2016
145690R1 Jun 2017
145696R1 Jul 2017
145696R2 Jul 2017
145697R1 Sep 2017
148186R1 Jan 2018
Tridural® 200mg 02296403 5000094
(UPC 6 2879100402 3)
143475R1 Mar 2017
143475R3 Mar 2017
145701R1 Jun 2017
148789R1 Jan 2018
Tridural® 300mg 02296411 5000095
(UPC 6 2879100403 0)
143757R1 Sep 2017
146629R1 Dec 2017

Background information

Tridural® is indicated for the management of moderate to moderately severe pain in adults who require treatment for several days or more.  The product is available in white, plain, bevelled edge, round, biconvex, oral tablets. All three dosage strengths (100mg, 200mg and 300mg) are similar in appearance but differ in weight and size (see images below).

Who is affected

Information for consumers

Patients receiving Tridural® tablets should be informed that the tablets may be marked or unmarked. The tablets can be taken regardless of whether or not they are marked; their formulation is the same. Markings on the tablets will be reinstated on future lots. Patients should be reminded to keep the tablets in the original prescription container, to avoid any potential confusion or medication errors.

If you have any confusion as to what strength of unmarked tablet you are using, you should not take it and return it to the pharmacy for clarification.

Information for health care professionals

Please follow these instructions when dispensing unmarked Tridural® tablets:

  • Inform patients that marked and unmarked tablets are available on the market and that they can continue to use the unmarked tablets as the formulation has not changed.
  • Remind patients of the importance of keeping the product in the original prescription container to avoid any potential confusion or medication errors.
  • Ensure to have a stock bottle available during dispensing to verify the dispensed product.
  • Avoid dispensing both marked and unmarked tablets within the same prescription.

Action taken by Health Canada

Health Canada is communicating this important safety information to healthcare professionals via the Recalls and Safety Alerts Database on the Healthy Canadians Web Site. This communication will be further distributed through the MedEffect™ e-Notice email notification system. Health Canada is working with the manufacturer to reinstate the markings on the Tridural® tablets.

Report health or safety concerns

Managing marketed health product-related side effects depends on health care professionals and consumers reporting them. Any case of serious or unexpected side effects in patients receiving Tridural® should be reported to Paladin Labs Inc. or Health Canada.

Paladin Labs Inc.
100 Boulevard Alexis Nihon, suite 600
Montréal, QC H4M2P2
Telephone: 1-888-376-7830

To correct your mailing address or fax number, contact Paladin Labs Inc.

You can report any suspected adverse reactions associated with the use of health products to Health Canada by:

  • Calling toll-free at 1-866-234-2345; or
  • Visiting MedEffect Canada's Web page on Adverse Reaction Reporting for information on how to report online, by mail or by fax.

For other health product inquiries related to this communication, contact Health Canada at:

Health Products and Food Branch Inspectorate
Telephone: 1-800-267-9675
Fax: 1-613-946-5636

Original signed by

Jean De Serres, Vice President Scientific Affaires


Select thumbnail to enlarge - opens in a new window